Eli Lilly injects $140M into U.S. insulin pen production; A third of women on asthma medications quit use during first few months of pregnancy;

@FiercePharma: Spectrum rejigs sales ops after Allos buyout, to tout its 3-drug stable. Prep for new ones, too. More | Follow @FiercePharma

> Eli Lilly ($LLY) is injection $140 million into U.S. insulin pen production at a plant in Indianapolis. Item

> Teva Pharmaceutical Industries ($TEVA) reported revenue reached $5 billion in the third quarter, up 14% from $4.3 billion in the corresponding quarter in 2011. News

> Drug-mixing pharmacy Ameridose recalled its products Wednesday, after federal health inspectors asked the company to improve its sterility testing. Report (sub. req.)

> The EMA's Pharmacovigilance Risk Assessment Committee put diclofenac-containing medicines (non-steroidal anti-inflammatory drugs) under safety review in relation to their possible cardiovascular risks. Report

> In a plan to save €2.7 billion ($3.5 billion), the region of Madrid will introduce a one-euro surcharge for medical prescriptions next year. Story

> India's government may lift a ban on pharma firm-sponsored tours for doctors. Article

> Aurobindo Pharma soared more than 8% to Rs 171 on the Bombay Stock Exchange, driven by abbreviated new drug application approvals received from the U.S. FDA. News

Medical Device News

 @FierceMedDev: Michael Mahoney, Boston Scientific's new CEO, inherits a giant in transition on day one. More | Follow @FierceMedDev

 @MarkHFierce: Advanced Cell Diagnostics pulled in $12 million in new Series B financing. More | Follow @MarkHFierce

 @DamianFierce: It's campaign season, and medical device companies are donating big. Find out how and to whom in our report. More | Follow @DamianFierce

> Medtronic closes $816M buyout of Chinese devicemaker. News

> BD completes $730M sale of labware unit. Item

> Disgraced former head of defunct French breast implant maker freed from jail. Article

Biotech News

 @FierceBiotech: Trending on FierceBiotech.com : The 2012 Biotech Graveyard. Special Report | Follow @FierceBiotech

 @JohnCFierce: Medivir would like everyone to know that JNJ's hep C drug came from them. Alios outlicensed Vertex drug, but they've always been low profile. | Follow @JohnCFierce

 @RyanMFierce: Sanofi deal bolsters Medidata in record quarter for revenue, boosts number of cloud customers in pharma. More | Follow @RyanMFierce

> Hurricane Sandy flooding wipes out years of drug research at NYU lab. Story

> Vertex partners with J&J, GlaxoSmithKline on new hep C combos. News

> FDA spurns new low-sodium drug from Cornerstone. Article

Vaccines News

 @AlisonBFierce: In search of a lasting flu vaccine: Researchers work to find decades of protection with one shot. More | Follow @AlisonBFierce

> Health officials clash over whether to scrap malaria program. Item

> Mumps vaccine succumbs to face-to-face contact. Story

> U.K.'s HPA lands $6.4M for anthrax vaccine research. Article

> Study: Flu vaccine protects against heart attacks. More

Pharma Manufacturing News

> Lonza whacking 500 jobs, 400 at Swiss API plant. Story

> Compounder recall may make drug shortages more severe. News

> Novartis adding $500M biologics plant in Singapore. Report

> Boston-area pharma plant goes up for auction to pay debts. More

And Finally... A study from the Netherlands shows almost a third of women on asthma medications stop using them during the first few months of pregnancy, despite advice that a mother's uncontrolled asthma is more dangerous to the developing fetus than the drugs. More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.